Pre-made Tocilizumab benchmark antibody ( Whole mAb, anti-IL6R therapeutic antibody, Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tocilizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tocilizumab (INN, trade name Actemra), also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.
| Products Name (INN Index) | Pre-Made Tocilizumab biosimilar, Whole mAb, Anti-IL6R Antibody: Anti-CD126/HIES5/IL-1Ra-1A/IL6Q/IL6QTL/gp80 therapeutic antibody |
|---|---|
| INN Name | Tocilizumab |
| Target | IL6R |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2004 |
| Year Recommended | 2004 |
| Companies | Assistance Publique Hopitaux de Paris,Charite – Universitatsmedizin Berlin,Chugai Pharmaceutical,Hospital for Special Surgery,JW Pharmaceutical,Roche,University Hospital Inselspital,University Hospit |
| Conditions Approved | Drug hypersensitivity,Giant cell arteritis,Giant lymph node hyperplasia,Juvenile rheumatoid arthritis,Rheumatoid arthritis,Vasculitis |
| Conditions Active | Adult-onset Still's disease,Osteoarthritis,Systemic scleroderma,Amyotrophic lateral sclerosis,Dermatomyositis,Familial Mediterranean fever,Polymyalgia rheumatica,Polymyositis,Pulmonary arterial hyper |
| Conditions Discontinued | Chronic lymphocytic leukaemia,Ankylosing spondylitis,Crohn's disease,Multiple myeloma,Pancreatic cancer,Systemic lupus erythematosus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL6R |
| Package |
